Technical Reports on Medical Equipment Equities -- ViewRay, Avinger, Nxstage, and Natus

Thursday, April 13, 2017 Medical Gadgets
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 13, 2017 /PRNewswire/ --

This morning has issued research reports on ViewRay Inc.

(NASDAQ: VRAY), Avinger Inc. (NASDAQ: AVGR), Nxstage Medical Inc. (NASDAQ: NXTM), and Natus Medical Inc. (NASDAQ: BABY). These companies belong to the Healthcare sector, with an industry focus on Medical Appliances and Equipment. According to Deloitte
Global's report, "2017 Global Health Care Outlook: Making Progress Against Persistent Challenges," released last February, global health care expenditures are projected to reach $8.7 trillion by 2020, driven by an aging population and associated chronic disease, innovative clinical advancements, and rising technology and labor costs. Today's research reports on the aforementioned stocks are downloadable for free upon registration at:


Oakwood Village, Ohio headquartered ViewRay Inc.'s stock finished Wednesday's session 0.94% lower at $7.36, with a total trading volume of 455,069 shares. The Company's shares have surged 26.24% in the past month, 131.45% over the previous three months, and 135.14% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 16.42% and 70.17%, respectively. Furthermore, shares of ViewRay, which through its subsidiary, ViewRay Technologies, Inc., designs, manufactures, and markets radiation therapy systems, have a Relative Strength Index (RSI) of 51.69.

On March 16th, 2017, ViewRay announced financial results for its Q4 and full year ended December 31st, 2016. For Q4 2016, total revenue was $16.1 million, total operating expenses were $9.3 million, and net loss was $(11.0) million. For the full year 2016, total revenue was $22.2 million, total operating expenses were $40.5 million, and net loss was $(50.6) million. Visit us today and access our complete research report on VRAY at:


Shares in Redwood City, California headquartered Avinger Inc. ended at $0.55, down 7.87% from the last trading session. The stock recorded a trading volume of 2.37 million shares, which was above its three months average volume of 556,210 shares. The Company's shares are trading 73.97% below their 50-day moving average. Moreover, shares of Avinger, which designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease in the US and Europe, have an RSI of 19.11.

On April 10th, 2017, Avinger provided an update on several aspects of its business, including preliminary results for the first quarter of 2017, an organizational realignment, and continued progress on product development and clinical initiatives. The Company also announced that it has been conducting a review of various strategic alternatives focused on maximizing shareholder value.

On April 12th, 2017, research firm Oppenheimer downgraded the Company's stock rating from 'Outperform' to 'Perform'. The complimentary report on AVGR can be downloaded at:

Nxstage Medical 

Lawrence, Massachusetts headquartered Nxstage Medical Inc.'s stock ended yesterday's session 0.79% lower at $26.21, with a total trading volume of 210,414 shares. The Company's shares are trading 4.20% above their 200-day moving average. Shares of the Company, which develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure, have an RSI of 40.27.

On April 06th, 2017, Nxstage Medical announced plans to release its financial results for Q1 ended March 31st, 2017 on Tuesday, May 09th, 2017, before the opening of the financial markets. The Company will also host a conference call at 9:00 a.m. ET on the same day to discuss its Q1 financial results. The call will be webcast live via the Company's website under the Investor Relations section. Register for free on and access the latest research report on NXTM at:

Natus Medical 

On Wednesday, shares in Pleasanton, California headquartered Natus Medical Inc. recorded a trading volume of 173,928 shares. The stock finished 0.89% lower at $38.80. The Company's shares have advanced 4.58% in the last one month, 2.78% in the previous three months, and 11.49% since the start of this year. The stock is trading above its 50-day moving average by 3.09%. Furthermore, shares of Natus Medical, which provides newborn care and neurology healthcare products and services worldwide, have an RSI of 56.03. Get free access to your research report on BABY at:

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store